Floatz logo

Pemigatinib

FGF Receptor Gene Mutation

Tianjin Medical University Second HospitalSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the FGF Receptor Gene Mutation cohort.

Asset / SponsorPhaseRating
Pemigatinib
Academic and Community Cancer Research United
Phase 2CCC
Pemigatinib
Academic and Community Cancer Research United
Phase 2CCC
Infigratinib
Novartis Pharmaceuticals
Phase 1CC

Same molecule, other indications

Pemigatinib is also rated in:

urothelial carcinomaDormant
B
Indicative ·
58 / 100
View asset →
non-small cell lung carcinomaDormant
B
Indicative ·
57 / 100
View asset →
cancerDormant
CCC
Indicative ·
55 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →